Optimising Patient Outcomes in mTNBC

In the study “Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer”, Patients were randomly assigned in a 1:1 ratio, with the use of a permuted block method and an interactive voice–Web response system, to receive atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel.

(N Engl J Med 2018; 379:2108-2121)

In the study “Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer”, In the PD-L1–positive subgroup, 64 of 185 patients (34.6%) in the atezolizumab–nab-paclitaxel group and 88 of 184 (47.8%) in the placebo–nab-paclitaxel group died. Because of the hierarchical statistical analysis procedure, formal testing of overall survival in the PD-L1–positive subgroup was not conducted at this interim analysis. However, Kaplan–Meier analyses showed a median overall survival of 25.0 months in the atezolizumab–nab-paclitaxel group and 15.5 months in the placebo–nab-paclitaxel group (stratified hazard ratio for death, 0.62; 95% CI, 0.45 to 0.86)

(N Engl J Med 2018; 379:2108-2121)

Metastatic samples have less PD-L1 positive (36%) than primary samples (44%).

(IMpassion 130 study: Emens et al. SABCS 2019)

(J Cortes KN355 ASCO 2020)

(Nina D’Abreo & Sylvia Adams, Nature Reviews, Clinical Oncology volume 16, pages 399–400(2019))